North America Cardiac Resynchronization Therapy (CRT) Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End User (Hospitals, Cardiac Centers, Ambulatory Surgical Centers, Other End Users) and By Country (U.S., Canada) Forecasts, 2026-2034

Market Overview

The North America Cardiac Resynchronization Therapy (CRT) Market size was valued at USD 1.86 billion in 2025 and is projected to grow from USD 2.03 billion in 2026 to reach USD 4.04 billion by 2034, growing at a CAGR of 8.99% during the forecast period 2026–2034.

Cardiac resynchronization therapy (CRT) is a treatment that assists the heart in beating at the correct rate. It employs a pacemaker to restore the heartbeat's normal timing pattern. The CRT pacemaker coordinates the synchronization of the heart's upper (atria) and lower (ventricles) chambers. It also regulates the synchronization between the heart's left and right sides.

The market for cardiac resynchronization therapy (CRT) was estimated to be worth USD 5.85 billion in 2021. One of the major trends accelerating market expansion is the rapid advancement of technology. The market is expanding due to sedentary lifestyle adoption, an aging population, and increased cardiovascular disease prevalence.

The CRT-D segment had the biggest market share because of high demand, accounting for 58.3% of all products in 2021. The CRT-P segment's fastest growth rate is anticipated due to numerous technological developments. The top competitors on the market include Medtronic, Abbott, Boston Scientific Corporation, BIOTRONIK, and MicroPort Scientific Corporation.

Highlights

• CRT-D dominates the market by Product.
• Hospitals dominate the market by End-User.
• U.S. dominates the market by Country.

Market Dynamics

North America Cardiac Resynchronization Therapy (crt) Market Drivers

Increasing Prevalence of Cardiovascular Diseases

Nearly half of all deaths from cardiovascular diseases are caused by sudden cardiac death, which continues to be a primary cause of mortality despite advancements in prevention and treatment. Devices for cardiac resynchronization therapy should see increased demand due to the rising prevalence of heart diseases and their risk factors. One of the top causes of death worldwide is heart failure. As of September 2020, the CDC estimates that 6.2 million persons with Heart failure plagued the US. 379,800 death certificates, or roughly 13.4%, listed it as a cause of death in 2018.

As a result, it is projected that the rising prevalence of cardiovascular disorders would increase demand for a range of therapeutic options, including cardiac resynchronization therapy devices.

North America Cardiac Resynchronization Therapy (crt) Market Restraints

Product Recall

Implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy (CRT-Ds), the Viva, Evera, Brava, Amplia, Claria, Visia, and Compia devices, as well as their distribution between August 31, 2012, and May 9, 2018, were all recalled by Medtronic in February 2021. An unexpected and abrupt decline in battery life led to the recall.

Boston Scientific Corporation started the INGENIO family of pacemakers and CRT-Ps recall in June 2021. ADVANTIO DR EL, INGENIO DR EL, and VITALIO DR EL are a few of them. Between November 2011 and August 2020, devices that have been recalled were distributed and manufactured between September 2011 and December 2018. In the US, some 48,000 gadgets were recalled. The possibility of the gadget entering safety mode led to the recall.

North America Cardiac Resynchronization Therapy (crt) Market Opportunities

The Growing Cases of Cardiovascular Diseases

One of the main factors fueling the growth of the cardiac resynchronization therapy market is the rise in surgical procedures and intensive care and critical care units.

North America Cardiac Resynchronization Therapy (CRT) Market Segmentation Analysis

By Product

The North America Cardiac Resynchronization Therapy (CRT) Market is segmented into CRT-Defibrillator and CRT-Pacemaker. CRT-Defibrillators combine cardiac resynchronization capabilities with implantable cardioverter-defibrillator functionality, allowing them to support heart rhythm synchronization while also providing protection against potentially life-threatening ventricular arrhythmias. CRT-Pacemakers are designed primarily to coordinate ventricular contractions and improve cardiac synchronization in eligible patients with heart failure and conduction abnormalities. Both product categories are widely used in cardiovascular care, with product selection depending on patient condition, arrhythmia risk, clinical guidelines, and physician assessment.

Increasing prevalence of heart failure, growing aging populations, rising diagnosis of cardiac rhythm disorders, and technological advancements in implantable cardiac devices are supporting demand across both product categories. CRT-Pacemakers represented a major product segment in North America, while CRT-Defibrillators continue to benefit from their ability to provide both resynchronization and defibrillation functions. Improvements in device miniaturization, battery life, remote monitoring, lead technology, and implantation techniques are expected to strengthen adoption of advanced CRT systems across the region.

Request Customizationto receive a tailored report.

By End User

The North America Cardiac Resynchronization Therapy (CRT) Market is segmented into Hospitals, Cardiac Centers, Ambulatory Surgical Centers, and Other End Users. Hospitals represent a major end-user segment because CRT implantation and related cardiac procedures require specialized infrastructure, cardiovascular specialists, diagnostic capabilities, and post-procedure monitoring. Cardiac centers provide specialized cardiovascular diagnosis, treatment, device implantation, and follow-up care, while ambulatory surgical centers are increasingly relevant for selected procedures that can be performed in outpatient settings. Other end users include specialized healthcare facilities and medical institutions involved in cardiac rhythm management and patient monitoring.

Growing demand for advanced cardiovascular care, increasing prevalence of heart failure and cardiac rhythm disorders, expansion of specialized cardiac facilities, and improvements in minimally invasive implantation techniques are supporting demand across end-user settings. Hospitals continue to benefit from their comprehensive cardiac-care infrastructure, while cardiac centers are gaining importance because of their specialized expertise and increasing focus on advanced rhythm-management procedures. Ambulatory surgical centers can benefit from the expansion of outpatient cardiovascular interventions, while remote monitoring and improved follow-up technologies are enhancing long-term management of CRT patients across North America.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The North American cardiac resynchronization therapy market is segmented by country into U.S. and Canada. U.S. dominates the country market and is expected to grow at a CAGR of 6.8% during the forecast period.

Due to its growing geriatric population and regulatory clearances, North America is anticipated to dominate the CRT market throughout the forecast period. The risk of developing chronic heart diseases might rise due to sedentary lifestyles, which may increase the requirement for cardiovascular care. Additionally, several medical gadget suppliers in this area offer cardiovascular care internationally. These businesses are concentrating on releasing cutting-edge products with attributes like enhanced battery life and miniaturization, which are predicted to fuel market expansion.

List of Key and Emerging Players in North America Cardiac Resynchronization Therapy (CRT) Market

• Abbott
• Boston Scientific Corporation
• Medtronic
• Biotronik SE & Co. Kg
• Microport Scientific Corporation
• LivaNova PLC
• Medico S.R.L.